Non-competitive androgen receptor inhibition in vitro and in vivo

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 17, 2009, Pages 7233-7238

  Jones, Jeremy O ^a   Bolton, Eric C ^a   Huang, Yong ^b   Feau, Clementine ^d   Guy, R Kiplin ^d   Yamamoto, Keith R ^a   Hann, Byron ^c   Diamond, Marc I ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Antagonist; Harmol; Pyrvinium

Indexed keywords

ANDROGEN RECEPTOR; DNA; HARMOL HYDROCHLORIDE; NATURAL PRODUCT; PYRVINIUM EMBONATE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; HARMINE; HARMOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DRUG DOSE ESCALATION; ENZYME ACTIVITY; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE ATROPHY; PROSTATE DISEASE; PROTEIN CONFORMATION; ANIMAL; CELL LINE; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM;

ANIMALS; CELL LINE; CELL PROLIFERATION; HARMINE; HUMANS; MALE; MICE; MOLECULAR STRUCTURE; PYRVINIUM COMPOUNDS; RECEPTORS, ANDROGEN;

EID: 66349124428     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0807282106     Document Type: Article

References (31)

1. Gelmann EP (2002) Molecular biology of the androgen receptor. J Clin Oncol 20:3001-3015.
2. Keller ET, Ershler WB, Chang C (1996) The androgen receptor: a mediator of diverse responses. Front Biosci 1:d59-71.
3. Chen CD, et al. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39.
4. Georget V, Terouanne B, Nicolas JC, Sultan C (2002) Mechanism of antiandrogen action: key role of hsp90 in conformational change and transcriptional activity of the androgen receptor. Biochemistry 41:11824-11831.
5. Schaufele F, et al. (2005) The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions. Proc Natl Acad Sci USA 102:9802-9807.
6. Jones JO, Diamond MI (2008) A cellular conformation-based screen for androgen receptor inhibitors. ACS Chem Biol 3:412-418.
7. Scher HI, Sawyers CL (2005) Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23:8253-8261.
8. Beck JW, Saavedra D, Antell GJ, Tejeiro B (1959) The treatment of pinworm infections in humans (enterobiasis) with pyrvinium chloride and pyrvinium pamoate. Am J Trop Med Hyg 8:349-352.
9. Thompson PE, Worley DE, Meisenhelder JE (1962) Anthelmintic studies on pyrvinium pamoate (Povan) and other drugs in rodents, dogs, and monkeys. Am J Trop Med Hyg 11:89-95.
10. Picada JN, da Silva KV, Erdtmann B, Henriques AT, Henriques JA (1997) Genotoxic effects of structurally related beta-carboline alkaloids. Mutat Res 379:135-149.
11. Horoszewicz JS, et al. (1980) The LNCaP cell line-a new model for studies on human prostatic carcinoma. Prog Clin Biol Res 37:115-132.
12. Klein KA, et al. (1997) Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 3:402-408.
13. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55.
14. Cleutjens KB, van Eekelen CC, van der Korput HA, Brinkmann AO, Trapman J (1996) Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem 271:6379-6388.
15. Nelson PS, et al. (2002) The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci USA 99:11890-11895.
16. Lin B, et al. (1999) Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res 59:4180-4184.
17. Amler LC, et al. (2000) Dysregulated expression of androgen-responsive and nonre-sponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer Res 60:6134-6141.
18. Bieberich CJ, Fujita K, He WW, Jay G (1996) Prostate-specific and androgen-dependent expression of a novel homeobox gene. J Biol Chem 271:31779-31782.
19. Kazmin D, et al. (2006) Linking ligand-induced alterations in androgen receptor structure to differential gene expression: a first step in the rational design of selective androgen receptor modulators. Mol Endocrinol 20:1201-1217.
20. Smith CL, O'Malley BW (2004) Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25:45-71.
21. Kang Z, Janne OA, Palvimo JJ (2004) Coregulator recruitment and histone modifica-tions in transcriptional regulation by the androgen receptor. Mol Endocrinol 18:2633-2648.
22. Shang Y, Myers M, Brown M (2002) Formation of the androgen receptor transcription complex. Mol Cell 9:601-610.
23. Hodgson MC, Astapova I, Hollenberg AN, Balk SP (2007) Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. Cancer Res 67:8388-8395.
24. Luo S, et al. (1997) Daily dosing with flutamide or Casodex exerts maximal antiandro-genic activity. Urology 50:913-919.
25. Matuo Y, Nishi N, Negi T, Tanaka Y, Wada F (1982) Isolation and characterization of androgen-dependent non-histone chromosomal protein from dorsolateral prostate of rats. Biochem Biophys Res Commun 109:334-340.
26. Waki H, et al. (2007) The small molecule harmine is an antidiabetic cell-type-specific regulator of PPARgamma expression. Cell Metab 5:357-370.
27. Solit DB, Scher HI, Rosen N (2003) Hsp90 as a therapeutic target in prostate cancer. Semin Oncol 30:709-716.
28. Hieronymus H, et al. (2006) Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 10:321-330.
29. Dobosy JR, Roberts JL, Fu VX, Jarrard DF (2007) The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hy-perplasia. J Urol 177:822-831.
30. Mellinghoff IK, et al. (2004) HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6:517-527.
31. Bolton EC, et al. (2007) Cell- and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev 21:2005-2017.